Ascentage Pharma Group International (AAPG) Invested Capital (2022 - 2025)

Ascentage Pharma Group International (AAPG) has reported Invested Capital for 4 consecutive years, with $85864.5 the latest figure, recorded in Q4 2025.

• Quarterly Invested Capital fell 97.96% year-over-year to $85864.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $250.5 million (changed N/A YoY) and the FY2025 annual result came in at $84744.1, down 97.99% from the prior year.
• Invested Capital declined to $85864.5 in Q4 2025 per AAPG's latest filing, from $4.2 million in the prior quarter.
• Over the last five years, Invested Capital for AAPG reached as high as $246.2 million in Q4 2023 and fell as low as $53851.4 in Q4 2022.
• A 4-year average of $62.6 million and a median of $2.1 million in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2023 — Invested Capital jumped 457150.1% — and 2024, when it plunged 98.29%.
• Year by year, Invested Capital stood at $53851.4 in 2022, then soared by 457150.1% to $246.2 million in 2023, then tumbled by 98.29% to $4.2 million in 2024, then tumbled by 97.96% to $85864.5 in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $85864.5, $4.2 million, and $246.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.